ROSE12 alone and with other drugs for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called ROSE12, given alone or with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapies. The study aims to see if ROSE12 is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be able to take care of yourself (getting around, doing light work) – this is called an ECOG score of 0 or 1.
- Your cancer must be advanced (has spread) and standard treatments have either stopped working, or there are no standard treatments available for you.
- You must have a fresh tumor sample (biopsy) available, or be able to provide one for testing.
- You cannot have significant heart or liver disease, or a history of severe immune-related side effects from a previous cancer immunotherapy.
- You cannot have untreated or active brain metastases (cancer that has spread to the brain).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immunotherapy drug called GLS-012, alone and with another drug (GLS-010), in people with advanced solid cancers that have worsened despite standard treatment. It aims to see how well the treatment works and how safe it is, especially when given in different combinations.
This study tests a new combination of drugs for advanced non-small cell lung cancer that has stopped responding to the first standard treatment. It is specifically for people whose tumors have certain gene changes (EGFR, ALK, or ROS1). The goal is to see if this combination can help control the cancer.
This trial tests two new injectable drugs for advanced solid tumors, especially kidney, head and neck, cervical, and ovarian cancers. The goal is to see if the combination is safe and if it can shrink tumors.
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
This trial tests a new cell therapy called ACE2016 for people with advanced solid tumors that have EGFR on their surface. It may be an option if you have tried at least two other treatments (including a targeted therapy) and your cancer is still growing.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.